(Q41564538)

3 October 2017

1 reference

title

Immunotherapy of bladder cancer (English)

1 reference

3 October 2017

1 reference

U. O. Nseyo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9259090

11 November 2024

D. L. Lamm

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9259090

11 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9259090

11 November 2024

publication date

1 September 1997

1 reference

3 October 2017

September 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9259090

full work available at URL

11 November 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F(SICI)1098-2388(199709%2F10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

DOI

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

https://onlinelibrary.wiley.com/doi/full/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

DOI

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Journal of Surgical Oncology

11 November 2024

published in

1 reference

3 October 2017

1 reference

3 October 2017

1 reference

3 October 2017

page(s)

342-349

1 reference

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C342%3A%3AAID-SSU8%3E3.0.CO%3B2-D

Molecular confirmation of bacillus Calmette-Guérin as the cause of pulmonary infection following urinary tract instillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291098-2388%28199709%2F10%2913%3A5%3C342%3A%3AAID-SSU8%3E3.0.CO%3B2-D

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

21 January 2018

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

The Plight of the Patient with Carcinoma in Situ of the Bladder

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Clinical application of a whole blood assay for human natural killer (NK) cell activity

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Internalization of bacille Calmette-Guerin by bladder tumor cells.

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Bacillus Calmette-Guerin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction.

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin--a useful marker of response?

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Immunotherapy of murine transitional cell carcinoma

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

BCG and cancer (first of two parts).

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Role of fibronectin in intravesical BCG therapy for superficial bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Intravesical bacille Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Natural history and treatment of low and high risk superficial bladder tumors

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

BCG in perspective: advances in the treatment of superficial bladder cancer.

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Megadose vitamins in bladder cancer: a double-blind clinical trial

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Local toxicity patterns associated with intravesical bacillus Calmette-Guérin: a Southwest Oncology Group Study

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Drug therapy of bacillus Calmette-Guérin sepsis

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Keyhole limpet hemocyanin immunotherapy of murine bladder cancer

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

New drugs and future developments in photodynamic therapy

11 November 2024

1 reference

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

https://api.crossref.org/works/10.1002/(SICI)1098-2388(199709/10)13:5%3C342::AID-SSU8%3E3.0.CO;2-D

10.1002/(SICI)1098-2388(199709/10)13:5<342::AID-SSU8>3.0.CO;2-D

11 November 2024

Identifiers

DOI

1 reference

3 October 2017

1 reference